Bramwell VH, Pritchard KI: Tamoxifen added to adjuvant chemo- therapy in premenopausal women with early breast cancer: Is it standard practice or still a subject for study? Eur J Cancer 35:1625-1627, 1999Bramwell VHC, Pritchard KI. Tamoxifen added to adjuvant chemotherapy in premenopausal women...
IL-7Rα staining on total and naïve CD4+ T cells of CD4ΔIl7ra mice was already decreased at 24 h after tamoxifen treatment and fully waned by 120 h in the blood, spleen, and LNs (Fig. 1A). The loss of IL-7Rα on total BM CD4+ T cells was less efficient than in the ...
Tamoxifen did not influence CIA in either group of patients. The addition of T to AC increases the risk of CIA in patients 40. Women 40 who experience CIA have a substantial chance of resuming menstruation even after 6 months of amenorrhea and this should be carefully considered when planning...
ICIs can now be used in more situations without concurrent chemotherapy or targeted therapy. For NSCLC, ICIs may be utilized either as first-line or secondary treatment [36]. For NSCLC patients treated with PD-1 inhibitors as opposed to chemotherapy, 5-year overall survival (OS) rates ranged ...
chemotherapy resistance, and relapse. Recently, proteostasis control was shown to be crucial for embryonic and adult stem cells to maintain pluripotency15. We previously showed that an appropriate level of UPR activation is required for the integrity of breast CSCs, while excess ER stress ameliorates...
Tamoxifen, a selective ER modulator (SERM), is predominantly antagonistic in breast cancer cells, hence its therapeutic effect. When tamoxifen binds to ER, co-activators are displaced by co-repressors in the ER-ERE complex (Shang et al., 2000). Established ER co-repressors bind ER via ...
Patients whose tumors were estrogen or progesterone receptor positive were offered tamoxifen for 5 years after chemotherapy. If patients were postmenopausal, an aromatase inhibitor was allowed. Follow-up To obtain an estimate of outcome and to monitor for long-term toxicities, patients were monitored ...
(cm) ≤2 2–5 45 NA 2,077 1,665 221 24 52 42 6 Initial Adjuvant Systemic Therapy None Tamoxifen only Chemotherapy only (AC, FAC or CMF) Tamoxifen and chemotherapy Other 1,676 1,274 725 296 16 42 32 18 8 Abbreviations: AC, adriamycin and cyclophosphamide; BCCA, British Columbia ...
This could be of importance in male breast cancer, where tamoxifen is considered to be the golden standard in adjuvant treatment, although there are no prospective studies that confirm its efficacy. There are no studies addressing the issue of tamo- xifen resistance in male breast cancer. In ...
GPER has been implicated in both the resistance to the ER antagonist tamoxifen and the up-regulation of aromatase levels, therefore leading to proliferative effects in tamoxifen-resistant BC cells [16,17,18]. In line with these findings, increased expression of GPER has been considered as a clin...